Gram-positive bacterial infections
MONDO:0021679Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.
Also known as: Gram Positive bacterial infections, Gram-positive bacterial infection, Gramme Positive bacterial infections, bacterial infection, Gram-positive, bacterial infections, Gram Positive, bacterial infections, Gram-positive, bacterial infections, Gramme Positive, infection, Gram-positive bacterial
251 clinical trials for this condition and its sub-types, 7 tagged with Gram-positive bacterial infections itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Gram-positive bacterial infections
-
Streptococcal infection 19 trials · 131 incl. sub-types
8 sub-types
- Pneumococcal infection 89 trials · 99 incl. sub-types Sub-types →
- Group B streptococcal infection 9 trials
- Streptococcal sore throat 8 trials
- Impetigo 5 trials Sub-types →
- Erysipelas 1 trial
- Streptococcal toxic-shock syndrome 1 trial
- Scarlet fever 0 trials
- Streptococcal meningitis 0 trials Sub-types →
-
Clostridium infectious disease 48 trials · 96 incl. sub-types
3 sub-types
- Tetanus 43 trials Sub-types →
- Botulism 5 trials Sub-types →
- Infection due to clostridium perfringens 0 trials Sub-types →
-
Bacillaceae infectious disease 1 trial · 20 incl. sub-types
1 sub-type
- Anthrax infection 17 trials · 20 incl. sub-types Sub-types →
-
1 sub-type
- Actinomycosis 0 trials Sub-types →
-
Erysipelothrix infectious disease 0 trials
1 sub-type
-
Infection caused by Bifidobacterium 0 trials
Most studied deeper sub-types
-
Can a new vaccine outsmart pneumococcal disease?
Vaccine Not yet recruitingThis trial tests a new pneumococcal vaccine, called PG4, in adults aged 18 to 49. Researchers compare three batches of PG4 to each other and to the current vaccine, Prevnar 20, to see if they produce similar immune responses and are equally safe. Participants receive one injectio…
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Sep 02, 2026 00:00 UTC
-
One shot, six protections: can a new vaccine match current standards?
Vaccine Not yet recruitingThis phase 3 trial tests a new combination vaccine called BK1803 in healthy infants aged 2 to 7 months. The vaccine aims to protect against six diseases: whooping cough, diphtheria, tetanus, polio, hepatitis B, and Haemophilus influenzae type b. Researchers compare BK1803 to a st…
Phase 3 • Sponsor: Tanabe Pharma Corporation • Aim: Vaccine
Last updated Aug 30, 2026 00:00 UTC
-
No-Needle tetanus shot? new patch trial begins
Vaccine Not yet recruitingThis first-in-human study tests a new microneedle patch (Miracus) that dissolves in the skin to deliver a tetanus vaccine without a needle. Thirty healthy adults will receive either an empty patch or one loaded with vaccine. Researchers will check safety, tolerability, and whethe…
Phase 4 • Sponsor: Microneedle Solutions Ltd • Aim: Vaccine
Last updated Jun 27, 2026 13:02 UTC
-
New vaccine for moms could shield babies from whooping cough
Vaccine Not yet recruitingThis study tests a new vaccine called TdaP2gen in 320 pregnant women in Thailand to see if it safely protects their babies from tetanus, diphtheria, and whooping cough. The vaccine is given during pregnancy, and researchers measure antibody levels in mothers and infants up to 18 …
Phase 4 • Sponsor: Chiang Mai University • Aim: Vaccine
Last updated Jun 27, 2026 13:01 UTC
-
New baby vaccine could fight pneumonia
Vaccine Not yet recruitingThis study tests a new vaccine to protect babies against pneumococcal infections, which can cause pneumonia and meningitis. About 500 healthy infants will receive either the new vaccine or an existing one. Researchers will check if the new vaccine triggers a strong immune respons…
Phase 3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:35 UTC
-
New vaccine trial aims to shield teens and adults from whooping cough
Vaccine Not yet recruitingThis early-stage trial is testing a new combination vaccine that protects against whooping cough, diphtheria, and tetanus (Tdap) in people aged 10 and older. Researchers want to see if different doses are safe and trigger an immune response. The study involves 96 volunteers and c…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 12:00 UTC
-
New Low-Dose tdap vaccine trial aims to boost protection with fewer side effects
Vaccine Not yet recruitingThis study tests a new version of the Tdap vaccine (which protects against tetanus, diphtheria, and whooping cough) that has reduced antigens. The goal is to see if it is safe and triggers a strong immune response in people aged 6 and up. Around 660 volunteers will receive either…
Phase 1/2 • Sponsor: Institute of Medical Biology, Chinese Academy of Medical Sciences • Aim: Vaccine
Last updated Jun 27, 2026 09:06 UTC
-
Can a pneumonia vaccine protect the most vulnerable children?
Vaccine Not yet recruitingThis study tests whether a pneumococcal vaccine (Pneumosil) can produce a strong immune response in children aged 6-59 months who are hospitalised with severe acute malnutrition. Half the children will receive the pneumococcal vaccine, and the other half will receive a typhoid va…
Phase 4 • Sponsor: Nick Fancourt • Aim: Vaccine
Last updated Jun 27, 2026 08:05 UTC
-
Engineered yeast pill takes on superbug c. diff in first human trial
Disease control Not yet recruitingThis early-stage trial tests an oral capsule containing a genetically modified probiotic yeast designed to neutralize toxins produced by C. diff bacteria. The study first evaluates safety in healthy adults, then in people at risk for recurrent C. diff infection. Participants take…
Phase 1 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Bacteria-Based immunotherapy targets pancreatic tumors in first human test
Disease control Not yet recruitingResearchers are testing a new immunotherapy called Lm-LLO-TT in adults with advanced pancreatic ductal adenocarcinoma that has already been treated with chemotherapy. Lm-LLO-TT uses a weakened form of Listeria bacteria engineered to carry a tetanus toxoid antigen, aiming to spark…
Phase 1 • Sponsor: Loki Therapeutics, Inc. • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Can an antibody that blocks a immune protein ease myasthenia gravis?
Disease control Not yet recruitingResearchers are testing an experimental antibody called EA5 in adults with generalized myasthenia gravis whose blood contains antibodies against the acetylcholine receptor and who have not tried complement inhibitor drugs. EA5 targets complement protein C5, part of the immune cas…
Phase 1 • Sponsor: Shanghai Lanyi Therapeutics Co., Ltd. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Can a potato starch shake off Drug-Resistant gut bacteria?
Disease control Not yet recruitingThis trial tests whether a dietary fiber called resistant potato starch can reduce the amount of drug-resistant bacteria living in the gut. The study enrolls Veterans who carry these bacteria without symptoms, and half will take the starch daily while the other half takes a place…
Phase 2 • Sponsor: VA Office of Research and Development • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pneumonia vaccine put to the test in babies
Disease control Not yet recruitingThis early-stage study tests a new pneumococcal vaccine (Pn-MAPS30plus) in 60 healthy infants to see if it is safe and what side effects it may cause. Babies will receive three doses starting around 2 months old, followed by a booster at 12-15 months. The study compares the new v…
Phase 1 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New antibiotic strategy could shorten hospital stays for heart infections
Disease control Not yet recruitingThis pilot study tests a long-acting antibiotic called oritavancin for treating gram-positive heart infections, such as infective endocarditis. The goal is to see if weekly IV doses can replace the usual weeks-long hospital stays and daily antibiotics. The study will enroll 20 ad…
Phase 2 • Sponsor: Kirby Institute • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Compression stockings may let patients skip Long-Term antibiotics for recurring skin infections
Disease control Not yet recruitingThis study tests whether wearing compression stockings alone can prevent repeat episodes of erysipelas (a bacterial skin infection) as well as the usual approach of antibiotics plus stockings. About 200 adults who have had at least two infections in the same leg will be randomly …
Phase 4 • Sponsor: University Hospital, Tours • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a common diabetes pill protect the brain after a stroke?
Disease control Not yet recruitingThis study tests whether canagliflozin, a diabetes drug, can reduce dangerous brain swelling and bleeding in people who have had a severe stroke and are receiving clot-removal therapy. About 150 adults will be randomly assigned to take the drug for 14 days or receive standard car…
Phase 4 • Sponsor: Taichung Veterans General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Could a sweetener beat a gut infection? new trial explores xylitol for c. diff in IBD
Disease control Not yet recruitingThis study tests if xylitol, a common sweetener, can safely clear C. difficile bacteria from the gut in people with inflammatory bowel disease (IBD). About 99 adults with mild or inactive IBD will take either a low or high dose of xylitol or a placebo for four weeks. Researchers …
Phase 1 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study to test anthrax drug in bioterror attack scenario
Disease control Not yet recruitingThis study will evaluate how well the drug raxibacumab works and how safe it is for people who have symptoms of inhalational anthrax after a large-scale exposure, such as a bioterrorist attack. Up to 100 people of all ages, including pregnant women and children, who receive the d…
Phase 4 • Sponsor: Emergent BioSolutions • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Anthrax drug under the microscope: will it save lives?
Disease control Not yet recruitingThis study follows up to 10 people with severe anthrax who receive a treatment called AIGIV. Researchers will track how many patients survive and whether the drug causes serious side effects. The goal is to learn more about how well AIGIV works and how it behaves in the body.
Sponsor: Emergent BioSolutions • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Emergency anthrax drug trial set to launch if outbreak strikes
Disease control Not yet recruitingThis study will test a medicine called AIGIV for people who have breathed in anthrax germs during a large-scale emergency. The goal is to see if the drug helps more people survive and to check for side effects. The study will only start if a major anthrax event happens, and it wi…
Sponsor: Emergent BioSolutions • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could a sweetener beat a gut infection? early trial tests xylitol for c. diff in IBD patients
Disease control Not yet recruitingThis pilot study tests whether xylitol, a common sugar alcohol, can safely clear C. difficile bacteria from the guts of people with inflammatory bowel disease (IBD). About 69 adults with mild or inactive IBD will take different doses of xylitol for up to 8 weeks. Researchers will…
Early phase 1 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for IBD patients: can a better antibiotic stop c. diff for good?
Disease control Not yet recruitingThis study compares two antibiotics, fidaxomicin and vancomycin, to see which one is better at clearing C. difficile bacteria from the gut in people with inflammatory bowel disease (IBD). About 60 adults with IBD will take one of the two antibiotics for 10 days and be followed fo…
Phase 4 • Sponsor: Brigham and Women's Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Spit test could replace needles for tetanus check
Diagnosis Not yet recruitingThis study aims to create a quick, non-invasive test using saliva to see if someone has enough antibodies to fight tetanus. Instead of drawing blood, a small saliva sample on a test strip would give results in 10-15 minutes. The test is designed for low- and middle-income areas w…
Sponsor: University of Birmingham • Aim: Diagnosis
Last updated Jun 27, 2026 09:09 UTC
-
Text message nudge could save thousands from pneumonia
Prevention Not yet recruitingThis study tests whether a simple WhatsApp message reminding people turning 65 in Chile to get their free pneumococcal vaccine can increase vaccination rates. Over 43,000 adults will be randomly assigned to receive the reminder or not, and researchers will track who gets vaccinat…
Sponsor: Pablo Tomás Valenzuela García • Aim: Prevention
Last updated Jun 27, 2026 14:01 UTC
-
Can a simple vaccine keep COPD patients out of the hospital?
Prevention Not yet recruitingThis large trial will study whether flu and pneumonia vaccines can reduce serious flare-ups and medical costs in people aged 45-80 with COPD. About 7,000 participants will be split into four groups: flu vaccine, pneumonia vaccine, both, or no vaccine. Researchers will track lung …
Phase 4 • Sponsor: Jiangsu Province Centers for Disease Control and Prevention • Aim: Prevention
Last updated Jun 27, 2026 13:07 UTC
-
New shot aims to block deadly tetanus after dirty wounds
Prevention Not yet recruitingThis study tests a new medicine called SNA02-48 to see if it can prevent tetanus in people who have had a high-risk wound, like a deep cut or puncture from a dirty object. About 600 adults will receive either the new injection or the standard treatment (human tetanus immunoglobul…
Phase 3 • Sponsor: Sinovac Life Sciences Co., Ltd. • Aim: Prevention
Last updated Jun 27, 2026 13:04 UTC
-
Which vaccine schedule works best? new study aims to protect babies from pneumococcal disease
Prevention Not yet recruitingThis study compares two schedules (2+1 vs 3+1 doses) of a 13-valent pneumococcal vaccine in 210 healthy infants starting at 2 months old. Researchers will measure antibody levels and track side effects to find the best way to prevent pneumococcal infections.
Sponsor: Beijing Center for Disease Control and Prevention • Aim: Prevention
Last updated Jun 27, 2026 12:32 UTC
-
Bile acid breakthrough: could a Decades-Old pill stop c. diff in its tracks?
Prevention Not yet recruitingThis early-phase trial tests whether adding Ursodeoxycholic Acid (UDCA) to standard antibiotics can prevent Clostridioides difficile (C. diff) infection from returning. About 30 adults with C. diff and risk factors for recurrence will take UDCA three times daily for up to eight w…
Early phase 1 • Sponsor: Medical College of Wisconsin • Aim: Prevention
Last updated Jun 27, 2026 12:25 UTC
-
New anthrax vaccine under review for Post-Exposure protection
Prevention Not yet recruitingThis study will look at 250 people who received the CYFENDUS anthrax vaccine after being exposed to anthrax bacteria during a mass event. Researchers want to see if the vaccine, given along with antibiotics, can prevent inhalational anthrax and anthrax meningitis. The study is ob…
Sponsor: Emergent BioSolutions • Aim: Prevention
Last updated Jun 27, 2026 08:03 UTC
-
Gut bacteria may help pancreatic surgery recovery
Symptom relief Not yet recruitingThis study tests whether a probiotic called Clostridium butyricum CBM588 can reduce diarrhea and improve quality of life in people who have had their pancreas removed due to cancer or other growths. About 158 patients will take either the probiotic or a placebo for three months a…
Sponsor: Casa di Cura Dott. Pederzoli • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Could a cold spray or buzzy gadget make shots less painful?
Symptom relief Not yet recruitingThis study tests whether using a cold spray or a Buzzy device (a vibrating cold pack) can reduce pain and fear during penicillin injections. Ninety adults receiving intramuscular penicillin will be randomly assigned to one of three groups: cold spray, Buzzy device, or standard ca…
Sponsor: Inonu University • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Is your nose fueling infected eczema and scabies sores?
Knowledge-focused Not yet recruitingResearchers are studying where the bacteria that infect skin sores come from in people with scabies or atopic dermatitis. They will compare bacteria grown from infected skin lesions with bacteria from nasal swabs to see if the same species appear in both places. A group of health…
Sponsor: Istanbul Medeniyet University • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can a Caregiver's opinion sway an older Adult's decision to get the pneumonia vaccine?
Knowledge-focused Not yet recruitingResearchers in Panama survey adults age 50 and older about pneumococcal disease and the PCV21 vaccine, which protects against pneumonia and other serious infections. One group covers ages 50 to 64; another covers adults 65 and older plus a caregiver who helps them. Each person an…
Sponsor: Endpoints Site Network • Aim: Knowledge-focused
Last updated Sep 11, 2026 00:00 UTC
-
Tetanus immunity under the microscope: do antibodies hold up after 2.5 years?
Knowledge-focused Not yet recruitingThis study checks how long protection from a tetanus vaccine lasts. Researchers take blood samples from 240 people who received the vaccine or a control in an earlier trial, 2.5 years after their shots. They measure antibody levels to see if they still meet protective thresholds.…
Sponsor: CanSino Biologics Inc. • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Vaccine Follow-Up: how long does protection last in babies?
Knowledge-focused Not yet recruitingThis study follows 100 infants who received a pneumococcal vaccine in an earlier trial. Researchers will take a small blood sample to measure antibody levels one and two years after vaccination. The goal is to see how long protection against pneumococcal infections lasts. No new …
Sponsor: CanSino Biologics Inc. • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Will a single DTP vaccine dose protect for a decade? study tracks antibodies
Knowledge-focused Not yet recruitingThis study follows 160 people who previously received a 5-component DTP vaccine (protecting against diphtheria, tetanus, and pertussis) to see how long their immune protection lasts. Blood samples are taken at 2.5, 5, and 10 years after vaccination to measure antibody levels. The…
Sponsor: CanSino Biologics Inc. • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Does the setting of care affect whether kids finish their antibiotics?
Knowledge-focused Not yet recruitingThis observational study looks at whether children aged 3 months to 16 years are more likely to complete their full course of antibiotics when prescribed at a primary care clinic versus a hospital emergency department. Researchers surveyed parents by phone after treatment ended t…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
FMT vs antibiotics: which works better Long-Term for c. diff?
Knowledge-focused Not yet recruitingThis study looks at adults who had a C. diff infection and were treated with either a fecal transplant (FMT) or antibiotics alone. Researchers want to see if FMT leads to healthier gut bacteria and fewer health problems years later. Participants will give blood, stool, and urine …
Sponsor: Umeå University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Anthrax drug under the microscope: new study tracks Real-World use
Knowledge-focused Not yet recruitingThis observational study will follow up to 10 people in the U.S. who have a confirmed case of systemic anthrax and are treated with the drug raxibacumab. Researchers will track survival, side effects, and drug levels in the blood to better understand how well the treatment works.…
Sponsor: Emergent BioSolutions • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Immune cell clues may unlock better HS treatment
Knowledge-focused Not yet recruitingThis study looks at how certain immune cells, called MAIT cells, behave in people with hidradenitis suppurativa (HS), a painful skin condition. Researchers will take skin and blood samples from 45 adults with HS and compare them to samples from people with other skin diseases. Th…
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC